Stock版 - 4 Biotech With 60% to 100% Upside Potential |
|---|
|
|
|
|
|
|
W***n
发帖数: 11530 | 1 4 Biotech Catalyst Stocks to Buy With 60% to 100% Upside Potential
By Lee Jackson November 20, 2014 8:55 am EST
In the world of biotech investing, there are some sure-fire ways for stocks
to move. Pipeline announcements, clinical data and regulatory approval all
can move the needle as catalysts for stocks in the industry. A new report
from the biotech team at Stifel has a self-described plethora of catalysts
from companies that are presenting at the firm’s annual health care
conference.
We screened the stocks in the Stifel report for those that were rated Buy at
the firm and had the biggest upside to the analysts’ price objectives.
Array BioPharma Inc. (NASDAQ: ARRY) is a top small cap to buy at Stifel. The
company focuses on the discovery, development and commercialization of
small molecule drugs to treat patients with cancer and inflammatory diseases
, primarily in North America, Europe and the Asia-Pacific. The company’s
MEK inhibitors, binimetinib and selumetinib, are currently advancing in six
Phase 3 trials, and Array’s partners expect the firm’s first regulatory
filing next year with top line results from the other trials available in
2016. In addition, it continues to collect data on the wholly owned
filanesib program in two Phase 2 multiple myeloma trials, including a
randomized combination trial with Kyprolis. With the progress, the company
expects potential commercial revenues within the next two years.
The Stifel price target is $6. The Thomson/First Call consensus is higher at
$7. Shares closed Wednesday at $3.53. Hitting the Stifel target would be a
monster 65% gain.
ALSO READ: 10 Companies That Will Not Be Saved by the Bull Market Alone
Cempra Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. It announced this week that it
has received authorization under its existing contract for the next phase of
its contract with the Biomedical Advanced Research and Development
Authority (BARDA) that will provide funding of $16.0 million for two
clinical studies of solithromycin. The Stifel team views the initial read on
the Solitaire-Oral study as indicating there may be label expansion
possibilities for solithromycin.
The Stifel price target is $22, and the consensus target is $19.50. The
stock closed Wednesday at $13.22. Trading to the Stifel target would be a 63
% gain.
GlycoMimetics Inc. (NASDAQ: GLYC) announced Monday that healthy volunteers
in a Phase 1 clinical study of GMI-1271 tolerated the drug candidate well,
and that the pharmacokinetics for the drug candidate were as predicted based
on preclinical data. The findings represent positive top-line results from
a Phase 1 trial designed to evaluate the safety, tolerability and
pharmacokinetics of GMI-1271, the GlycoMimetics-discovered novel and
proprietary E-selectin antagonist. Based on the data, GlycoMimetics is
planning a Phase 1/2 trial of GMI-1271 as an adjunct to standard
chemotherapy in patients with acute myeloid leukemia. The Stifel team thinks
the drug and clinical work will be very visible at the American Society of
Hematology (ASH) conference to be held next month.
The Stifel price target is $13, and the consensus is higher at $14.67. The
shares closed Wednesday at $7.78. Trading to the Stifel target would be a 72
% gain.
MacroGenics Inc. (NASDAQ: MGNX) is a clinical-stage biopharmaceutical
company focused on discovering and developing innovative monoclonal antibody
-based therapeutics for the treatment of cancer, as well as autoimmune
disorders and infectious diseases. The company generates its pipeline of
product candidates from its proprietary suite of next-generation antibody-
based technology platforms. It announced this week that pre-clinical data on
MGD011, a humanized CD19 x CD3 dual-affinity re-targeting (DART) protein,
will be highlighted in a poster presentation at the ASH.
The Stifel team feels that the company has best-in-class assets in a very
relevant treatment area. The firm puts a $51 price target on the stock, and
the consensus target is $45.83. Shares closed at $23.69. Hitting the Stifel
target would be over a 100% gain for shareholders.
ALSO READ: 7 Analyst Stock Picks Under $10 With Massive Upside Calls
These are extremely aggressive and potentially volatile stocks and trades.
They are only suitable for speculative accounts with a very high risk
tolerance. With that caveat in mind, some big gains could be there for
biotech traders.
By Lee Jackson | W***n
发帖数: 11530 | 2 Man, it also has - 60% to 100% Downside Potential
hahaha |
|
|
|
|
|
|
|
